Last reviewed · How we verify
NCT02972216
A Post-marketing Surveillance Study to Evaluate the Effectiveness and Safety of Docetaxel-Based Chemotherapy
trial testing Nolbaxol in Nonsmall Cell Lung Cancer in 40 participants. Completed.
1 October 2016
Quick facts
| Lead sponsor | Yung Shin Pharm. Ind. Co., Ltd. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 1 November 2014 |
| Primary completion | 1 October 2016 |
Drugs / interventions tested
- Nolbaxol — full drug profile →
- Taxotere (Docetaxel) — full drug profile →
- cisplatin (cisplatin) — full drug profile →
Conditions studied
- Nonsmall Cell Lung Cancer — all drugs for Nonsmall Cell Lung Cancer →
- Squamous Cell Carcinoma of the Head and Neck — all drugs for Squamous Cell Carcinoma of the Head and Neck →
Sponsor
Yung Shin Pharm. Ind. Co., Ltd. — full company profile →
Who can join
20 and older, any sex, with Nonsmall Cell Lung Cancer or Squamous Cell Carcinoma of the Head and Neck. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Progression-Free Survival (PFS)
Time frame: Every 8 weeks after post-dosing follow-up visit, and conducted until disease progression or up to 11 months.
Sponsor's own description
A Post-marketing Surveillance Study to Evaluate the Effectiveness and Safety of Docetaxel-Based Chemotherapy
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02972216
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Nonsmall Cell Lung Cancer
Currently open trials in the same condition.
- NCT04900935 — Patient-centered, Optimal Integration of Survivorship and Palliative Care · NA · recruiting
- NCT06147570 — A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer · Phase 2 · recruiting
- NCT05358249 — Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation · Phase 1, PHASE2 · active not recruiting
- NCT03753685 — X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases · Phase 2 · active not recruiting
- NCT03778814 — TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors · Phase 1 · recruiting
Other Yung Shin Pharm. Ind. Co., Ltd. trials
Trials by the same sponsor.
- NCT06600282 — Bioequivalence of Two Formulations of Parecoxib in Healthy Volunteers Under Fasting Conditions · Phase 4 · not yet recruiting
- NCT05654090 — Evaluate Bioequivalence of Burotam (1/1 g/Vial) · Phase 4 · unknown
- NCT05496725 — Evaluate Bioequivalence of Micafungin (50mg/Vial) · Phase 4 · completed
- NCT04585412 — Evaluate Bioequivalence of Palonosetron (0.25mg/5mL) · Phase 4 · completed
- NCT04552353 — Evaluate Bioequivalence of Voriconazole(200mg/Vial) . · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02972216 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yung Shin Pharm. Ind. Co., Ltd.
- Last refreshed: 21 November 2016
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02972216.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing